Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Symphogen stocks up

New Symphogen cash to take cancer antibody mixture program to market

After topping up its coffers last week, Symphogen A/S now has the cash and long-term investor base to see the Danish antibody platform play through its goal of building out a pipeline and taking at least one product to market.

The company secured €41 million ($53.4 million) in an extension of a tranched series E round co-led by existing investors Novo A/S and Danish pension fund PKA.

Also participating was Danica Pension, another Danish pension fund that made its first direct investment in Symphogen after previously

Read the full 849 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers